Connect with us

Science

The Many Ways Kennedy Is Already Undermining Vaccines

Published

on

The Many Ways Kennedy Is Already Undermining Vaccines

During his Senate confirmation hearings to be health secretary, Robert F. Kennedy Jr. presented himself as a supporter of vaccines. But in office, he and the agencies he leads have taken far-reaching, sometimes subtle steps to undermine confidence in vaccine efficacy and safety.

The National Institutes of Health halted funding for researchers who study vaccine hesitancy and hoped to find ways to overcome it. It also canceled programs intended to discover new vaccines to prevent future pandemics.

The Centers for Disease Control and Prevention shelved an advertising campaign for the flu shot. Mr. Kennedy has said inaccurately that the scientists who advise the C.D.C. on vaccines have “severe, severe conflicts of interest” in promoting the products and cannot be trusted.

The Health and Human Services Department cut billions of dollars to state health agencies, including funds needed to modernize state programs for childhood immunization. Mr. Kennedy said in a televised interview on Wednesday that he was unaware of this widely reported development.

The Food and Drug Administration canceled an open meeting on flu vaccines with scientific advisers, later holding it behind closed doors. A top official paused the agency’s review of Novavax’s Covid vaccine. In a televised interview last week, Mr. Kennedy said falsely that similarly created vaccines don’t work against respiratory viruses.

Advertisement

Some scientists said they saw a pattern: an effort to erode support for routine vaccination, and for the scientists who have long held it up as a public health goal.

“This is a simultaneous process of increasing the likelihood that you will hear his voice and decreasing the likelihood that you’ll hear other voices,” Kathleen Hall Jamieson, director of the Annenberg Public Policy Center, said of Mr. Kennedy.

He is “decertifying other voices of authority,” she said.

H.H.S. disagreed that Mr. Kennedy was working against vaccines.

“Secretary Kennedy is not anti-vaccine; he is pro-safety,” Andrew Nixon, a department spokesman, said in a statement. “His focus has always been on ensuring that vaccines are rigorously tested for efficacy and safety.”

Advertisement

The statement continued, “We are taking action so that Americans get the transparency they deserve and can make informed decisions about their health.”

After attending the funeral of an unvaccinated child who died of measles in West Texas on Sunday, Mr. Kennedy endorsed the measles vaccine on X as “the most effective way to prevent the spread of measles.”

But he has also described vaccination as a personal choice with poorly understood risks and suggested that miracle treatments were readily available. On Sunday, he praised two local doctors on social media who have promoted dubious, potentially harmful, treatments for measles.

Even as cases of measles in the United States have surged past 600 in 22 jurisdictions, Mr. Kennedy has claimed in a recent interview that the measles vaccine causes deaths every year (untrue); that it causes encephalitis, blindness and “all the illnesses that measles itself causes” (untrue); and that the vaccine’s effect wanes so dramatically that older adults are “essentially unvaccinated” (untrue).

According to an email obtained by The New York Times, H.H.S. intends to revise its web pages to include statements like “The decision to vaccinate is a personal one” and “People should also be informed about the potential adverse events associated with vaccines.” (Vaccines are already administered only after patients provide informed consent, as required by law.)

Advertisement

Tensions with mainstream experts came into sharp focus last week, when Dr. Peter Marks, the top vaccine regulator, resigned under pressure from the F.D.A.

“It has become clear that truth and transparency are not desired by the secretary, but rather he wishes subservient confirmation of his misinformation and lies,” Dr. Marks said in his resignation letter.

Mr. Kennedy’s position on vaccines has raised alarm for decades. But it has become particularly notable now, against a backdrop of rising skepticism of vaccines and worsening outbreaks of measles and bird flu, experts said.

The M.M.R. vaccine — a combination product to prevent measles, mumps and rubella that has been available since 1971 — has long been a target of anti-vaccine campaigns because of the disproved theory that it can cause autism. Mr. Kennedy has said that he would like to revisit the issue, in part to assuage parents’ fears that the vaccines are unsafe.

But he has hired David Geier to re-examine the data. Senator Bill Cassidy, Republican of Louisiana, a doctor and the chairman of the Senate Health Committee, has sharply criticized the decision to spend tax dollars testing a discredited hypothesis even as the administration is cutting billions for other research.

Advertisement

“If we’re pissing away money over here,” he said last month, “that’s less money that we have to actually go after the true reason.”

The refusal to accept scientific consensus is “disturbing, because then we get into very strange territory where it’s somebody’s hunch that this does or doesn’t happen, or does or doesn’t work,” said Stephen Jameson, president of the American Association of Immunologists.

In interviews, Mr. Kennedy has downplayed risks of measles and emphasized what he sees as the benefits of infection.

“Everybody got measles, and measles gave you protected lifetime protection against measles infection — the vaccine doesn’t do that,” he said in an interview on Fox News.

Two doses of the M.M.R. vaccine do provide decades-long immunity. And while immunity from the infection may last a lifetime, “people also suffer the consequences of that natural infection,” Dr. Jameson said.

Advertisement

One consequence was discovered just a few years ago: A measles infection can destroy the immune system’s memory of other invading pathogens, leaving the body vulnerable to them again.

Measles kills roughly 1 in every 1,000 infected people, and 11 percent of those infected this year have been hospitalized, many of them children under 5, according to the C.D.C. Two girls, ages 6 and 8, died in West Texas.

By contrast, side effects after vaccination are uncommon. But Mr. Kennedy has suggested that people should apprise themselves of the risks before opting for the shot.

The phrasing implies that “if you are more fully informed, you might make a different decision,” said Dr. Jamieson, of the Annenberg center.

Doctors have long expected health secretaries and the C.D.C. to urge widespread vaccination unequivocally amid an outbreak, and in the past they have.

Advertisement

But Mr. Kennedy has spoken enthusiastically about cod liver oil, a steroid and an antibiotic that are not standard therapies. Some of those treatments may be making children more sick.

“The messaging I’m seeing is focused on potential treatments for measles,” said Dr. Sean O’Leary, chair of the infectious disease committee for the American Academy of Pediatrics.

At his confirmation hearing, Mr. Kennedy promised that he would not change the C.D.C.’s childhood vaccination schedule. About two weeks later, he announced a new commission that would scrutinize it.

The schedule is based on recommendations from the Advisory Committee on Immunization Practices, a panel of medical experts who review safety and effectiveness data, potential interactions with other drugs and the ideal timing to maximize protection.

At his confirmation hearing, Mr. Kennedy claimed that 97 percent of A.C.I.P. members had financial conflicts of interest. He has long held, without evidence, that federal regulators are compromised and are hiding information about the risks of vaccines.

Advertisement

“It’s frankly false,” said Dr. O’Leary, who serves as a liaison to the committee from the pediatric academy.

Mr. Kennedy’s statistic came from a 2009 report that found that 97 percent of disclosure forms had errors, such as missing dates or information in the wrong section.

In fact, A.C.I.P. members are carefully screened for major conflicts of interest, and they cannot hold stocks or serve on advisory boards or speaker bureaus affiliated with vaccine manufacturers.

On the rare occasion that members have indirect conflicts of interest — for example, if an institution at which they work receives money from a drug manufacturer — they disclose the conflict and recuse themselves from related votes.

The committee’s votes were public and often heavily debated.

Advertisement

“When I was C.D.C. director, people flew in from Korea and all over the world to observe the A.C.I.P. meetings, because they were a model of transparency,” said Dr. Thomas R. Frieden, who led the agency from 2009 to 2017.

Mr. Kennedy has repeatedly promised greater transparency and accountability, but he has proposed ending public comment on health policies.

His department canceled a meeting of the A.C.I.P. in February at which members were set to discuss vaccines for meningitis and flu, rescheduling it for April.

The department also canceled a meeting to discuss the seasonal flu vaccine. Officials met later without the agency’s scientific advisers.

“After all that conversation about how they want to be transparent, one of the first things he does is take things behind closed doors and diminish the amount of public input we’re getting,” said Dr. Georges Benjamin, executive director of the American Public Health Association.

Advertisement

At his confirmation hearing, Mr. Kennedy repeated a fringe theory that Black Americans should not receive the same vaccines as others because they “have a much stronger reaction.”

Senator Angela Alsobrooks, Democrat of Maryland, who is Black, admonished him for his “dangerous” opinion: “Your voice would be a voice that parents would listen to.”

Two weeks later, at a clinic for teenage mothers in Denver, a 19-year-old woman refused all vaccines for herself and her 1-year-old son — including the measles and chickenpox shots he was supposed to have that day.

She told the pediatrician, Dr. Hana Smith, who described the incident, that she had read online that vaccines were bad for people with more melanin in their skin.

There are reams of evidence to the contrary. Still, it quickly became clear to Dr. Smith that nothing was going to change her patient’s mind.

Advertisement

“No matter how much information I can give to the contrary on it, the damage is already done,” Dr. Smith said.

Misinformation is particularly difficult to counter, Dr. Smith said, “when it’s someone that has a leadership position, especially within the health care system.”

Science

Not everyone is leaving California. A new commercial battery maker just landed in Sacramento

Published

on

Not everyone is leaving California. A new commercial battery maker just landed in Sacramento

The lithium-ion batteries that supply much of today’s clean energy come with some infamous drawbacks, from fire risk to reliance on foreign mining.

Alternatives have been slow to get off the ground.

But California startup Peak Energy announced Wednesday it’s building a factory in Sacramento that will be the first in the U.S. to make sodium-ion battery packs at commercial scale.

Sodium-ion batteries have long held promise. They are made from cheap and abundant sodium ash deposits. The materials are less prone to overheating, so they don’t have the fire risk of lithium.

But they also store less energy per cubic inch. That means they have to be bigger and heavier, which makes them harder to fit into electric vehicles. So far, they’ve struggled to compete.

Advertisement

Peak Energy thinks it has an edge. The company focuses on storage systems big enough to power large data centers, factories and whole segments of the grid, where battery size matters less.

The company already delivers battery packs out of a small pilot project in San Francisco, but it has gotten $1.1 billion in preorders and now needs more space.

CEO and co-founder Landon Mossburg said its first products, each about the size of a shipping container, will begin rolling out in early 2027.

“We’re a 3-year-old company with over a billion in deposit-backed customer contracts, we’ve got grid deployment already, and all those products are exceeding expectations on the grid,” Mossburg said. “Those are really great signals.”

He founded Peak after working at Tesla and the now-folded Swedish battery company Northvolt. The battery cells, which make up the systems, will come from China.

Advertisement

Customers for Peak who have put down a deposit include independent power providers Jupiter Power, Energy Vault and RWE Americas, who are connecting utilities, and increasingly data centers, with batteries. Peak also works with utilities directly including one unnamed customer in California, and is “in fairly advanced discussions with two of the major hyperscalers,” Mossburg said.

Not everyone is so optimistic about the technology. Lithium-ion batteries are still cheaper, at least up front.

“Sodium-ion batteries attracted considerable interest when lithium-ion battery prices surged in 2022,” said Isshu Kikuma, an energy storage analyst at BloombergNEF. Since then, he noted, those prices have come down.

And as with lithium-ion battery chemistry, Asian manufacturers already have an edge.

“Sodium-ion cells are currently exclusively manufactured on a commercial scale within China,” said Evan Hartley, a research manager at the Benchmark Minerals consulting firm. Large producers such as BYD and CATL are spending enormous amounts to research and develop new products, he said.

Advertisement

Other U.S.-based sodium-ion startups have floundered of late. Natron Energy canceled plans to produce sodium-ion battery cells in North Carolina last year after funding difficulties. Bedrock Materials, which was making sodium-ion batteries for EVs, also closed up shop, citing a bet on a lithium supply shortage that hadn’t panned out.

But Peak Energy’s model is different, Mossburg said. Unlike Natron, it won’t be trying to make the batteries that go into their systems at first. They’ll import them, initially from China and later from other countries in Asia.

“While working at Tesla, I saw the advantage of focusing on a great end product that customers want before you try to bite off more of the scope,” Mossburg said.

Last month, Peak announced a partnership with General Motors to develop their own cells.

Once up and running, Peak Energy’s Sacramento factory will make three to four battery systems per day, each filled with almost 8,000 battery cells. One system can power hundreds of homes for four hours, Mossburg said. Customers will deploy tens or hundreds in a single project, “basically creating a power-plant sized battery” that can store power and supply the grid when energy is expensive, or directly serve facilities like data centers.

Advertisement

Although sodium-ion batteries cost more than lithium ones, Mossburg said Peak Energy’s battery systems still save customers money: The technology does not heat up like lithium, so it eliminates the need for expensive cooling technology.

“Because lithium-ion needs to actively cool, you’re basically paying to refrigerate your batteries or using energy to refrigerate your batteries, and we don’t need any of that stuff,” said Mossburg.

The upshot is a battery that’s cheaper, quieter, and safer.

“Safety is a major advantage for sodium-ion batteries,” Kikuma said.

That could matter in California, where battery opposition has surged after a fire at a Moss Landing energy storage facility drove the evacuation of 1,200 residents and contaminated nearby wetlands.

Advertisement

California has typically been a hub of battery research and development, not manufacturing. Mossburg said Peak Energy, which also has offices in Colorado, chose Sacramento for its proximity to a talented workforce, a growing energy storage market and the company’s engineering teams in Burlingame. He said the factory would create 239 new jobs.

The company hasn’t received any federal clean energy tax credits, but it got a $10.5-million tax credit from the state of California.

While sodium-ion is likely to remain a small fraction of the global battery market, Kikuma said stationary energy storage is one of the fastest growing applications for sodium-ion batteries.

Mossburg sees Peak as being ahead in this corner of the market.

“Everybody from CATL to GM have sort of validated now what we’re doing,” he said. “The market is trying to catch up.”

Advertisement
Continue Reading

Science

What’s the deal with … coffee enemas?

Published

on

What’s the deal with … coffee enemas?

It seems like nothing is off limits these days in L.A.’s most woo-woo wellness scenes. From ayahuasca circles and mail-order ketamine lozenges to off-label peptide injections, IV drips and longevity treatments, there’s a seemingly infinite number of ways to look and feel better that people will swear by in this town. Coffee enemas — mostly for digestive issues, but also for a host of other emotional and physiological conditions — is on that alleged miracle menu, and far more common than I even realized before I started writing this article.

“Oh, I have a friend who does that,” “Oh, my cousin swears by it,” I began hearing from people as soon as I started looking for interviewees.

Reddit contains hundreds of anecdotes — both enthusiastic and cautionary — about coffee enemas, which involve a person, often on their own, but sometimes with the assistance of an alternative health practitioner, filling a bag with coffee fluid, inserting a tube into their rectum, and slowly allowing the liquid to be absorbed. “Beware of coffee enemas,” reads the subject line of a post from a woman who did them regularly for a decade and reports feelings of exhaustion, spaciness and cravings when she tries to stop. “Caffeine in any form only (temporarily) masks and provides salve toward bigger, unaddressed issue(s),” she writes.

In response, another user — a person with Stage 4 ovarian cancer — jumps in to defend the practice. “Let’s respect what we are all doing, whether we agree or not,” they write. “I am doing conventional [treatment] in conjunction with alternative (I believe there is a place for both). I haven’t felt this good since my diagnosis. I feel light, have never felt jittery and chemotherapy had me so constipated I would cry.”

Advertisement

Over the last couple of decades, the interest in digestive health has grown exponentially, prompted by research on the gut-brain connection. According to a report by Grand View Research, the global gut health market was valued at $60.31 billion in 2025 and is projected to reach $114.83 billion by 2033. The growing number of people who are quietly (and often devoutly) doing coffee enemas is a part of this larger trend, which also includes fasting, cleanses, colonics, probiotics, food allergy and stool tests, and a number of other products and services intended to address everything from irregular or uncomfortable bowel movements to energy levels and mood. But what’s the deal with coffee enemas? And are they actually good for you? We talked to a wide range of people with an equally wide range of opinions.

Five enemas a day? Inside the controversial Gerson therapy

The pro-enema Reddit user coping with Stage 4 cancer posted that they do three coffee enemas daily. They discovered the practice through Gerson, an institute founded in 1978 to promote a treatment plan initially developed for tuberculosis, and later for cancer, migraines and other chronic conditions, by German American physician Dr. Max Gerson in the 1930s. If you visit the Gerson Institute website, the supplies for a coffee enema — organic therapy blend coffee ($9.75) and the complete enema bucket kit with catheter ($19) — are listed in its store. It has clinics in Tijuana, Budapest and Shangri-La, China.

Nicole Ferrer-Clement, executive director of the Gerson Institute, says the treatment plan, referred to as the Gerson therapy, has four parts, with five coffee enemas per day being the first part and an essential component of the protocol. The other parts include a vegetarian, fat-free diet, three juices (carrot, carrot and apple, and a green juice) and supplements. The idea behind the coffee enemas, she says, is that compounds (theobromine, theophylline, caffeine) in coffee stimulate the liver to produce more bile, which helps carry toxins out of the body through the digestive tract. Ferrer-Clement says this is important for cancer patients, whose livers may already be compromised while processing toxins released during treatment. Even though many people reach out to Gerson about coffee enemas for general health and wellness and constipation, she says that’s not generally something they recommend. The therapy remains controversial among mainstream oncologists, in part because there are few rigorous clinical studies evaluating its efficacy.

“We want research on [coffee enemas], we’re happy and open to do that, if someone is going to fund it,” Ferrer-Clement says, estimating the institute has treated thousands of patients over the years.

In addition to using coffee enemas to treat cancer, the majority of users online report turning to them for constipation. Many anecdotes are from people who tried more conventional medicine for digestive issues and, from a place of desperation, decided to look elsewhere for solutions. Others, like Chevanni Davids, a 33-year-old South African man living in Bali, use them to maintain a general sense of well-being. Davids — who grew up in South Africa, where culturally it’s common for grandmothers to administer enemas to children in rural areas — does a coffee enema twice per month. He was introduced to the practice of enemas with coffee by someone he describes as a Brazilian grandmother or elder. He swears by the practice, saying it’s kept his bowel movements regular and his emotional state at an equilibrium. Davids warns against doing them too frequently, however. “The addiction is a thing,” he says, “because it feels so, so good. After you do it once, you’re going to say, ‘I’m going to do that tomorrow.’”

Advertisement

A doctor’s take

Unsurprisingly, given that most people tend to find coffee enemas after reports of being failed by Western medicine, mainstream gastroenterology is not on board with this practice. “Coffee enemas are based on the ill-conceived idea that you’re washing toxins out of your colon, but your colon is not an organ that clears toxins like the liver,” says Dr. Barry Zamost, a gastroenterologist who was in private practice in Long Beach for more than 40 years. “This just flies in the face of all logic and physiology that any doctor has learned for 100 years.”

Zamost remembers first hearing of coffee enemas decades ago when Michael Landon, an actor best known for his roles on “Little House on the Prairie” and “Bonanza,” decided to reject chemotherapy in favor of alternative treatments following a pancreatic cancer diagnosis in 1991. Over his four decades in private practice, Zamost says he frequently saw patients with constipation who were frustrated and trying alternate methods, but that oral therapies such as laxatives, supplements and prescription medications remain the most safe and effective treatments.

A review of case reports from nine people who self-administered coffee enemas also concluded that there’s insufficient evidence to prove that the practice is helpful, and that it could be harmful, to the colon. Zamost says he thinks it’s unlikely for someone to cause themselves serious harm by doing coffee enemas, although it’s happened. He also says that in rare cases that enemas — not with coffee — are appropriate for patients who are severely constipated to provide temporary relief. But, generally, he doesn’t see any benefit to using coffee. As for why people report loving them? That’s easy enough to explain, he says. “Everybody feels better after a bowel movement. So if you gave yourself an enema that really made you feel like you were emptied, you’ll feel good. It doesn’t mean your health is better.”

The takeaway

Coffee enemas are likely not harmful when done in moderation, but we don’t have much more than anecdotal evidence at this point to indicate that they’re helpful either.

Advertisement
Continue Reading

Science

Contributor: The crucial medical question that AI can’t ever answer

Published

on

Contributor: The crucial medical question that AI can’t ever answer

One of us got a call last spring from a longtime friend. The story was familiar: two doctors, an MRI, an online AI tool, a stack of articles — and one anxious question. “Everything tells me something different. The AI says I might need surgery. What should I do?”

We believe there’s one key response to anyone in this all-too-common conundrum: “What matters most to you?”

There was a long pause.

That pause is one of the most important moments in modern healthcare — and it is exactly the question artificial intelligence is unable to address.

In our careers as physicians and researchers, we have found, clearly and repeatedly, that for many common conditions the medical evidence does not point to a single “right” answer. The biology is often close. What determines the success of an outcome is whether the choice fits the person making it.

Advertisement

Some patients with back pain want the fastest possible return to physically demanding work, even if it means surgery. Others want to avoid an operation at almost any cost, even if recovery takes longer. The scan may look the same. The lives behind the scan are not.

That insight is becoming critically important as artificial intelligence moves deeper into everyday health decisions.

In our research on AI and clinical decision-making, we’ve studied what happens when systems are trained to optimize medical outcomes but are blind to human values. In plain English, today’s AI is very good at telling you what usually works for people like you with similar demographics and medical histories. It is far less capable of understanding what you are trying to protect, avoid or prioritize.

This matters because some of the most common and most expensive medical decisions are not purely biological. Should someone with low-risk prostate cancer choose surgery, radiation or careful monitoring? Should a person with atrial fibrillation undergo a procedure or manage the condition with medication? Should a patient with chronic knee or back pain operate now or try months of physical therapy to see whether surgery can be avoided?

In these situations, the medical differences between options are often small or uncertain. What makes the biggest difference is whether the treatment aligns with the patient’s goals: tolerance for risk, willingness to undergo recovery, ability to adhere to long-term therapy or simply what kind of life they want to live.
AI systems can calculate probabilities. They cannot determine what those probabilities mean to a particular person.

Advertisement

In some respects, artificial intelligence may know more medicine than any individual physician. It can synthesize millions of scientific papers, clinical studies and patient records in seconds. Yet it knows remarkably little about the person sitting across from it. AI does not know a patient’s goals, fears, obligations, tolerance for risk or personal definition of a good outcome. And because it knows little about either the patient or the physician, it knows even less about the conversation between them — the place where facts, values and trust come together to produce the right decision for a particular person.

A second patient story brought this home. A retired teacher was referred after an AI-based symptom checker flagged a heart rhythm abnormality and “favored” an invasive procedure. The patient arrived frightened, convinced there was one correct path. When we talked, it became clear that what mattered most was avoiding a long recovery and staying healthy enough to travel to see grandchildren.

Medication and monitoring — less dramatic, but well-supported by evidence — fit those goals better. The AI wasn’t wrong. It just didn’t know what mattered.
This blind spot is not trivial. Roughly a quarter of U.S. healthcare spending flows through decisions in which patient preferences meaningfully affect outcomes. When those preferences are ignored — by people or by algorithms — care becomes misaligned. That can mean unnecessary procedures, poor adherence, regret and rising costs without better health.

So what should consumers do when an app, portal or “smart” tool recommends a course of action?

Start with three questions.

Advertisement

First: “Best for whom?” If a tool says one option is best, ask whether it means best on average — or best for someone with your priorities.

Second: “What does this system not know about me?”
AI can see lab values and imaging results. It cannot see your job, your family responsibilities, your fears or what you are trying to get back to.

Third: “What happens if I wait or choose differently?”
Many important medical decisions are not emergencies. When options are close, taking time to reflect is often part of good care.

Artificial intelligence is becoming a powerful partner in medicine. It can help explain options, surface evidence and reduce confusion. But it should inform human decisions, not replace them.

AI may know more medicine than any physician.

Advertisement

It knows far less about any patient.

And it knows least about the conversation between them.

The most important variable in your healthcare is not in any algorithm. It is you.

James N. Weinstein is a surgeon and former chief executive of Dartmouth Health. He is a clinical professor at Northwestern University’s Kellogg School of Management and global head of Health Futures at Microsoft, which develops AI systems. Ogan Gurel is a physician and assistant professor at the University of Texas at Arlington, where he researches AI, causal inference and patient decision-making.

Advertisement
Continue Reading
Advertisement

Trending